Retrospective study of incidence/prevalence of pigmentary maculopathy and retinopathy in patients receiving pentosan polysulfate sodium
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0313497 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Zhong Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, Global Epidemiology, Horsham, PA, United States of America. Hauptthemen laut MEDLINE: Pentosan Sulfuric Polyester, Cystitis, Interstitial, Macular Degeneration. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate prevalence and incidence rates of pigmentary maculopathy and retinopathy (PM/PR), and visual acuity (VA) changes in patients exposed to pentosan polysulfate sodium (PPS) and in patients with interstitial cystitis (IC) not exposed to PPS.
Methods
This is a retrospective cohort study (January 2015–March 2021) which included adult de-identified patients from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and Komodo Health database. Three patient cohorts were identified: two PPS-exposed patient cohorts, and Non-PPS-exposed IC patient cohort. Key study outcomes included PM/PR/Any (defined based on prior literature regardless of PPS exposure) and PM/PR/PPS (further defined by an algorithm that was based on clinical notes and other protocol-prespecified criteria in PPS-exposed patients), and VA changes in each respective cohort.
Results
Prevalence of PM/PR/Any was relatively common in patients prior to PPS exposure (4.16%–8.43%). Incidence rate of PM/PR/PPS was uncommon in both PPS-exposed cohorts (0.13–0.15 per 100 person-years). Crude incidence rates of PM/PR/Any (based on ITT analysis) varied slightly across 3 study cohorts (2.13–2.81 and 2.38 per 100-person-years for PPS-exposed cohorts and Non-PPS-exposed IC cohort, respectively). Across all 3 study cohorts, patients with PM/PR/Any appeared to have approximately 2-fold higher proportion of 3 lines of VA worsening than those without PM/PR/Any.
Conclusion
Prevalence of PM/PR was common in patients prior to PPS exposure. Incidence of PM/PR/PPS that may be associated with PPS exposure was relatively uncommon. Crude incidence rates of PM/PR appeared similar across all patient cohorts regardless of PPS exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Janssen Research & Development, Global Epidemiology, Horsham, PA, United States of America.
- Janssen Research & Development, Titusville, NJ, United States of America.
- Janssen Research & Development, Horsham, PA, United States of America.
- Janssen Research & Development, Statistics and Decision Science, Raritan, NJ, United States of America.
- Johnson and Johnson Surgical Vision, Irvine, CA, United States of America.
- Janssen Research & Development, Global Epidemiology, Titusville, PA, United States of America.
ORCID-Profile: Zhong Yuan
Zitieren
APA
Yuan, Z., Vaughan, S., Jeffcoat, C., Hu, P., Yuson, R., Fife, D., & Borkar, D. (2025). Retrospective study of incidence/prevalence of pigmentary maculopathy and retinopathy in patients receiving pentosan polysulfate sodium. PLOS ONE. https://doi.org/10.1371/journal.pone.0313497
Vancouver
Yuan Z, Vaughan S, Jeffcoat C, Hu P, Yuson R, Fife D, et al. Retrospective study of incidence/prevalence of pigmentary maculopathy and retinopathy in patients receiving pentosan polysulfate sodium. PLOS ONE. 2025. doi:10.1371/journal.pone.0313497
BibTeX
@article{Yuan2025,
author = {Yuan, Zhong and Vaughan, Subusola and Jeffcoat, Carolyn and Hu, Peter and Yuson, Ritchie and Fife, Daniel and Borkar, Durga},
title = {Retrospective study of incidence/prevalence of pigmentary maculopathy and retinopathy in patients receiving pentosan polysulfate sodium},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0313497}
}
EUVIMED